Histogenics Corp (NASDAQ:HSGX) shares gapped down prior to trading on Tuesday . The stock had previously closed at $0.21, but opened at $0.20. Histogenics shares last traded at $0.19, with a volume of 3,417,532 shares traded.

Separately, ValuEngine upgraded shares of Histogenics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $2.44.

The company has a fifty day simple moving average of $0.19. The company has a market cap of $17.76 million, a price-to-earnings ratio of -0.24 and a beta of 3.27.

Histogenics (NASDAQ:HSGX) last issued its quarterly earnings data on Wednesday, May 15th. The biotechnology company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.05). Sell-side analysts expect that Histogenics Corp will post -0.03 EPS for the current year.

An institutional investor recently raised its position in Histogenics stock. Virtu Financial LLC grew its holdings in shares of Histogenics Corp (NASDAQ:HSGX) by 505.8% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 592,976 shares of the biotechnology company’s stock after purchasing an additional 495,096 shares during the quarter. Virtu Financial LLC owned approximately 0.63% of Histogenics worth $69,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 11.44% of the company’s stock.

Histogenics Company Profile (NASDAQ:HSGX)

Histogenics Corporation develops restorative cell therapies that would offer rapid-onset pain relief and restored function. The company was founded in 2000 and is headquartered in Waltham, Massachusetts.

Featured Article: Debt-To-Equity Ratio

Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.